CPS-Cancer Prevention & Survivorship Research Program
CPS-Cancer Prevention & Survivorship Research Program
批准号:
9567685
负责人:
DAN ALAN DIXON
金额:
$0.62万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Adolescent obesityAdultAdverse effectsAnimalsAreaAwardBehaviorBehavioralBiological MarkersBiologyBody Weight decreasedBreastCancer BiologyCancer Center Support GrantCancer ControlCancer SurvivorCancer SurvivorshipCatchment AreaChemopreventionClinicalCollaborationsColonColon CarcinomaComorbidityDevelopmentDiscipline of NursingDiseaseDrug usageEventExercise PhysiologyFundingFutureGastroenterologyGrantHealth PsychologyImpaired cognitionIndividualInterventionIntervention TrialJournalsKansasLeadershipLocal TherapyMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMalignant neoplasm of prostateMedical OncologyMentorsMissouriModelingMolecularMyocardial dysfunctionNatural ProductsNursesObesityOutcomePatient Outcomes AssessmentsPatientsPeer ReviewPeer Review GrantsPeripheral Nervous System DiseasesPhasePhysical activityPopulation ControlPositioning AttributePre-Clinical ModelPremalignantPreventionPrevention strategyPrevention trialPreventive InterventionPrimary PreventionProstatePublicationsPublishingQuality of lifeRadiobiologyRecurrenceResearchResearch PersonnelResource SharingRiskRuralScientistSecondary PreventionSiteSouthwest Oncology GroupSurgical OncologySystemic TherapyTestingTissuesTranslational ResearchTranslationsUnderserved PopulationWorkanalogbasebiomedical informaticscancer preventioncohortenergy balancehigh riskimprovedinter-institutionalmalignant breast neoplasmmembermetabolomicsnovelnutritionpreventprogramsresponse biomarkersuccesssurvivorshipweight loss intervention
中文摘要
癌症预防和生存-项目摘要
癌症预防和生存(CPS)专注于癌前生物学及其转化为初始癌症。
测试新的预防策略,以及旨在改善癌症生活质量的干预措施
幸存者在癌前生物学和风险生物标志物的主题,研究中心的组织变化,
作为恶性转化的指标或预测指标,以及开发新的
预防战略。在预防和生存转化研究主题中,来自
癌前生物学和风险生物标志物主题与行为和临床研究人员合作,
测试新战略。CPS与癌症控制和人口控制(CCPH)不同,
重点关注新生物标志物的发现以及预防和生存的早期测试
使用高风险个体的干预措施,而CCPH侧重于实施已知有效的
战略布局CPS有来自16个部门/部门的21名正式成员和10名准成员,他们具有癌症方面的专业知识
生物学,内科和外科肿瘤学,放射生物学,胃肠病学,护理学,临床健康心理学,
营养学、运动生理学和生物医学信息学。2015年,CPS增加了NCI的数量(12),
自2011年以来,CCSG提交的同行评审赠款总数(29)从6个增加到24个。七
同行评审赠款是多PI奖,从一个。NCI和同行评审资金总额增加
从1 804 303美元和6 244 484美元减至3 098 479美元和11 890 377美元。从2012年到2015年,有800多名患者
共进行了15次干预试验。这些试验中有12项是医生发起的,3项是同行评议的
资金。堪萨斯和密苏里州的成人肥胖率很高。因此,许多CPS干预性试验
与集水区合作伙伴密切合作,注重体育活动和减肥。CPS
自2012年以来,会员共发表了382篇文章,其中164篇(43%)是计划内的,127篇(33%)是
204个(54%)有机构间合作。45篇出版物(12%)
期刊影响因子≥ 8。CPS对KUCC做出了重要的领导贡献(主任和三名AD,主席
PRMC,SWOG生存委员会联合主席)和基于高度转化生物标志物的早期阶段
预防和生存试验通常与平行动物研究。SWOG椅子的位置有助于移动
有前途的试点到更大的合作组试验。KUCC通过共享资源为CPS做出贡献
试点资金。在未来,CPS将继续建立其优势的新的癌前模型,新的
风险和反应生物标志物,早期试验的高风险队列,
化学预防试验CPS将增加与CB的合作,以扩大生物标志物研究,
代谢组学,与D3 ET一起开发用于一级预防的天然产物类似物,与CCPH一起开发用于
增加差距和与集水区有关研究,以及教育倡议和辅导。
英文摘要
Cancer Prevention and Survivorship – Project Summary
Cancer Prevention and Survivorship (CPS) focuses on pre-cancerous biology and its translation into initial
testing of new prevention strategies, as well as interventions aimed at improving the quality of life for cancer
survivors. In the Pre-Cancerous Biology and Risk Biomarkers theme, research centers on tissue changes that
serve as indicators or predictors of malignant transformation and potential targets for developing new
preventive strategies. In the Prevention and Survivorship Translational Research theme, basic scientists from
the Pre-Cancerous Biology and Risk Biomarkers theme work with behavioral and clinical researchers for early
testing of new strategies. CPS is unique from Cancer Control and Population Control (CCPH) in that CPS
focuses on the discovery of new biomarkers and early phase testing of prevention and survivorship
interventions using high-risk individuals, whereas CCPH focuses on implementation of known effective
strategies. CPS has 21 full and 10 associate members from 16 departments/divisions with expertise in cancer
biology, medical and surgical oncology, radiation biology, gastroenterology, nursing, clinical health psychology,
nutrition, exercise physiology and biomedical informatics. In 2015, CPS increased the number of NCI (12) and
total peer-reviewed (29) funded grants from 6 and 24 since 2011, the previous CCSG submission. Seven of
the peer-reviewed grants are multi-PI awards, up from one. NCI and total peer-reviewed funding increased
from $1,804,303 and $6,244,484 to $3,098,479 and $11,890,377. From 2012-2015, over 800 patients were
accrued to 15 intervention trials. Twelve of these trials were investigator-initiated and three peer-reviewed
funded. Kansas and Missouri have high rates of adult obesity. Thus, many of the CPS interventional trials
focus on physical activity and weight reduction, in close collaboration with catchment area partners. CPS
members have published 382 articles since 2012 of which 164 (43%) had intra-programmatic, 127 (33%) had
inter-programmatic and 204 (54%) had inter-institutional collaborations. Forty-five publications (12%) had a
journal impact factor ≥ 8. CPS contributes to KUCC with significant leadership (Director and three ADs, Chair
PRMC, Co-chair SWOG Survivorship Committee) and highly translational biomarker based early phase
prevention and survivorship trials often with parallel animal studies. The SWOG chair position helps move
promising pilots into larger co-operative group trials. KUCC contributes to CPS both through shared resources
and pilot funding. In the future, CPS will continue to build on its strengths of novel pre-cancerous models, new
risk and response biomarkers, high-risk cohorts for early phase trials, energy balance and natural products in
chemoprevention trials. CPS will increase collaborations with CB to expand biomarker research in
metabolomics, with D3ET to develop natural product analogues for primary prevention and with CCPH to
increase disparity and catchment area-relevant research, as well as educational initiatives and mentoring.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy
-
批准号:10392415
-
项目类别:
-
资助金额:$58.17万
-
财政年份:2019
-
负责人:DAN ALAN DIXON
-
依托单位:
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy
-
批准号:10627821
-
项目类别:
-
资助金额:$58.17万
-
财政年份:2019
-
负责人:DAN ALAN DIXON
-
依托单位:
CPS-Cancer Prevention & Survivorship Research Program
-
批准号:9975744
-
项目类别:
-
资助金额:$5.84万
-
财政年份:2012
-
负责人:DAN ALAN DIXON
-
依托单位:
REGULATION OF COX-2 EXPRESSION IN INTESTINAL NEOPLASIA
-
批准号:7959759
-
项目类别:
-
资助金额:$13.32万
-
财政年份:2009
-
负责人:DAN ALAN DIXON
-
依托单位:
Post-Transcriptional Regulation in Colorectal Cancer
-
批准号:8616417
-
项目类别:
-
资助金额:$28.32万
-
财政年份:2009
-
负责人:DAN ALAN DIXON
-
依托单位:
Post-Transcriptional Regulation in Colorectal Cancer
-
批准号:8515341
-
项目类别:
-
资助金额:$28.57万
-
财政年份:2009
-
负责人:DAN ALAN DIXON
-
依托单位:
Post-Transcriptional Regulation in Colorectal Cancer
-
批准号:8114017
-
项目类别:
-
资助金额:$28.32万
-
财政年份:2009
-
负责人:DAN ALAN DIXON
-
依托单位:
Post-Transcriptional Regulation in Colorectal Cancer
-
批准号:7780251
-
项目类别:
-
资助金额:$29.19万
-
财政年份:2009
-
负责人:DAN ALAN DIXON
-
依托单位:
REGULATION OF COX-2 EXPRESSION IN INTESTINAL NEOPLASIA
-
批准号:7720813
-
项目类别:
-
资助金额:$17.72万
-
财政年份:2008
-
负责人:DAN ALAN DIXON
-
依托单位:
REGULATION OF COX-2 IN INTESTINAL NEOPLASIA
-
批准号:7610472
-
项目类别:
-
资助金额:$16.43万
-
财政年份:2007
-
负责人:DAN ALAN DIXON
-
依托单位:
COBRE: USC: REGULATION OF COX-2 IN INTESTINAL NEOPLASIA
-
批准号:7381898
-
项目类别:
-
资助金额:$15.08万
-
财政年份:2006
-
负责人:DAN ALAN DIXON
-
依托单位:
CPS-Cancer Prevention & Survivorship Research Program
-
批准号:9750132
-
项目类别:
-
资助金额:$1.67万
-
财政年份:--
-
负责人:DAN ALAN DIXON
-
依托单位:
CPS-Cancer Prevention & Survivorship Research Program
-
批准号:9750042
-
项目类别:
-
资助金额:$5.73万
-
财政年份:--
-
负责人:DAN ALAN DIXON
-
依托单位:
海外基金